Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

NCT03035188 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: Vismodegib

Sponsor

SRH Wald-Klinikum Gera GmbH